David M Thomas,,, Fracp

List of Publications by Year in Descending Order

178 papers	10,769 citations	49 h-index	102 g-index
196 ext. papers	12,646 ext. citations	8.7 avg, IF	6.23 L-index

#	Paper	IF	Citations
178	Rare germline variants in childhood cancer patients suspected of genetic predisposition to cancer. *Genes Chromosomes and Cancer*, **2022**, 61, 81-93	5	0
177	Delivering precision oncology to patients with cancer.. *Nature Medicine*, **2022**, 28, 658-665	50.5	7
176	Psychological predictors of cancer patientsRand their relativesRattitudes towards the return of genomic sequencing results.. *European Journal of Medical Genetics*, **2022**, 65, 104516	2.6	0
175	Germline PALB2 Variants and PARP Inhibitors in Endometrial Cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2021**, 19, 1212-1217	7.3	1
174	Psychological predictors of advanced cancer patientsRpreferences for return of results from comprehensive tumor genomic profiling. *American Journal of Medical Genetics, Part A*, **2021**,	2.5	1
173	Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions. *Genome Biology*, **2021**, 22, 109	18.3	6
172	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. *Cancer*, **2021**, 127, 2934-2942	6.4	11
171	Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. *Leukemia*, **2021**, 35, 3245-3256	10.7	10
170	Effectively communicating comprehensive tumor genomic profiling results: Mitigating uncertainty for advanced cancer patients. *Patient Education and Counseling*, **2021**, 105, 452-452	3.1	2
169	Fear of cancer recurrence in patients undergoing germline genome sequencing. *Supportive Care in Cancer*, **2021**, 29, 7289-7297	3.9	2
168	Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology. *Npj Precision Oncology*, **2021**, 5, 58	9.8	1
167	Longitudinal patterns in fear of cancer progression in patients with rare, advanced cancers undergoing comprehensive tumour genomic profiling. *Psycho-Oncology*, **2021**, 30, 1920-1929	3.9	
166	Value of whole-genome sequencing to Australian cancer patients and their first-degree relatives participating in a genomic sequencing study. *Journal of Genetic Counseling*, **2021**,	2.5	1
165	Germline variants underlie a subset of paediatric osteosarcoma. *Journal of Medical Genetics*, **2021**, 58, 20-24	5.8	2
164	Family communication about genomic sequencing: A qualitative study with cancer patients and relatives. *Patient Education and Counseling*, **2021**, 104, 944-952	3.1	2
163	Influence of lived experience on risk perception among women who received a breast cancer polygenic risk score: RAnother piece of the pieR. *Journal of Genetic Counseling*, **2021**, 30, 849-860	2.5	3
162	The experiences and needs of Australian medical oncologists in integrating comprehensive genomic profiling into clinical care: a nation-wide survey. *Oncotarget*, **2021**, 12, 2169-2176	3.3	1

161	ClinSV: clinical grade structural and copy number variant detection from whole genome sequencing data. *Genome Medicine*, **2021**, 13, 32	14.4	9
160	Disparities in Cancer Care: The Example of Sarcoma-In Search of Solutions for a Global Issue. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2021**, 41, 1-7	7.1	0
159	Does undertaking genome sequencing prompt actual and planned lifestyle-related behavior change in cancer patients and survivors? A qualitative study. *Journal of Psychosocial Oncology Research and Practice*, **2021**, 3, e059	0.7	0
158	Implementation of the Australasian Teletrial Model: Translating idea into action using implementation science frameworks. *Journal of Telemedicine and Telecare*, **2021**, 1357633X211017805	6.8	2
157	Novel RET Fusion Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma.. *JCO Precision Oncology*, **2021**, 5, 1160-1165	3.6	1
156	PD-1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma. *Cancer Reports*, **2021**, 4, e1327	1.5	2
155	In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer.. *EMBO Molecular Medicine*, **2021**, e14608	12	1
154	Unlocking Access to Broad Molecular Profiling: Benefits, Barriers, and Policy Solutions.. *Public Health Genomics*, **2021**, 1-10	1.9	
153	MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer. *Science*, **2020**, 368, 1127-1131	33.3	33
152	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. *JAMA Oncology*, **2020**, 6, 724-734	13.4	60
151	Advanced Cancer Patient Knowledge of and Attitudes towards Tumor Molecular Profiling. *Translational Oncology*, **2020**, 13, 100799	4.9	3
150	Cancer patientsRviews and understanding of genome sequencing: a qualitative study. *Journal of Medical Genetics*, **2020**, 57, 671-676	5.8	7
149	The Medical Genome Reference Bank contains whole genome and phenotype data of 2570 healthy elderly. *Nature Communications*, **2020**, 11, 435	17.4	20
148	Who should access germline genome sequencing? A mixed methods study of patient views. *Clinical Genetics*, **2020**, 97, 329-337	4	1
147	Penetrance of Different Cancer Types in Families with Li-Fraumeni Syndrome: A Validation Study Using Multicenter Cohorts. *Cancer Research*, **2020**, 80, 354-360	10.1	9
146	Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. *Nature Medicine*, **2020**, 26, 1742-1753	50.5	69
145	Advanced cancer patient preferences for receiving molecular profiling results. *Psycho-Oncology*, **2020**, 29, 1533-1539	3.9	1
144	Assessment of the Value of Tumor Variation Profiling Perceived by Patients With Cancer. *JAMA Network Open*, **2020**, 3, e204721	10.4	4

143	BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. *Journal of the National Cancer Institute*, **2020**, 112, 1190-1203	9.7	12
142	Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. *OncoImmunology*, **2020**, 9, 1747340	7.2	49
141	Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. *Lancet, The*, **2019**, 394, 478-487	40	148
140	Identification of novel sarcoma risk genes using a two-stage genome wide DNA sequencing strategy in cancer cluster families and population case and control cohorts. *BMC Medical Genetics*, **2019**, 20, 69	2.1	1
139	A quantitative model to predict pathogenicity of missense variants in the TP53 gene. *Human Mutation*, **2019**, 40, 788-800	4.7	14
138	Diagnosis of fusion genes using targeted RNA sequencing. *Nature Communications*, **2019**, 10, 1388	17.4	70
137	Genomic stratification and liquid biopsy in a rare adrenocortical carcinoma (ACC) case, with dual lung metastases. *Journal of Physical Education and Sports Management*, **2019**, 5,	2.8	7
136	FISH analysis of selected soft tissue tumors: Diagnostic experience in a tertiary center. *Asia-Pacific Journal of Clinical Oncology*, **2019**, 15, 38-47	1.9	8
135	Patient perspectives on molecular tumor profiling: "Why wouldnR t you?". *BMC Cancer*, **2019**, 19, 753	4.8	12
134	Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. *Modern Pathology*, **2019**, 32, 1772-1785	9.8	33
133	Therapeutic implications of germline genetic findings in cancer. *Nature Reviews Clinical Oncology*, **2019**, 16, 386-396	19.4	24
132	Infiltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23. *Cancer Discovery*, **2019**, 9, 1511-1519	24.4	13
131	Translating genomic risk into an early detection strategy for sarcoma. *Genes Chromosomes and Cancer*, **2019**, 58, 130-136	5	3
130	The Medical Genome Reference Bank: a whole-genome data resource of 4000 healthy elderly individuals. Rationale and cohort design. *European Journal of Human Genetics*, **2019**, 27, 308-316	5.3	17
129	A comparison of Australian and French families affected by sarcoma: perceptions of genetics and incidental findings. *Personalized Medicine*, **2018**, 15, 13-24	2.2	
128	Optical mapping reveals a higher level of genomic architecture of chained fusions in cancer. *Genome Research*, **2018**, 28, 726-738	9.7	27
127	Development and Pilot Testing of a Decision Aid for Genomic Research Participants Notified of Clinically Actionable Research Findings for Cancer Risk. *Journal of Genetic Counseling*, **2018**, 27, 1055-1066	2.5	4
126	The PiGeOn project: protocol for a longitudinal study examining psychosocial, behavioural and ethical issues and outcomes in cancer tumour genomic profiling. *BMC Cancer*, **2018**, 18, 389	4.8	7

125	The PiGeOn project: protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer. *BMC Cancer*, **2018**, 18, 454	4.8	10
124	Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients. *International Journal of Cancer*, **2018**, 142, 1594-1601	7.5	19
123	Locally Aggressive Connective Tissue Tumors. *Journal of Clinical Oncology*, **2018**, 36, 202-209	2.2	33
122	Trials and tribulations: improving outcomes for adolescents and young adults with rare and low survival cancers. *Medical Journal of Australia*, **2018**, 209, 330-332	4	3
121	Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal-seeking studies of targeted therapies for rare and neglected cancers. *Medical Journal of Australia*, **2018**, 209, 354-355	4	19
120	Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing. *Lung Cancer*, **2017**, 107, 22-35	5.9	21
119	Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?. *Familial Cancer*, **2017**, 16, 423-432	3	31
118	IFN-□s required for cytotoxic T cell-dependent cancer genome immunoediting. *Nature Communications*, **2017**, 8, 14607	17.4	80
117	Estimating Mutation Carrier Probability in Families with Li-Fraumeni Syndrome Using LFSPRO. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 837-844	4	7
116	Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes. *Cancer Research*, **2017**, 77, 4279-4292	10.1	26
115	Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. *JAMA Oncology*, **2017**, 3, 1634-1639	13.4	107
114	Surveillance in Germline TP53 Mutation Carriers Utilizing Whole-Body Magnetic Resonance Imaging. *JAMA Oncology*, **2017**, 3, 1735-1736	13.4	9
113	Is Li-Fraumeni syndrome really much more common?. *Human Mutation*, **2017**, 38, 1619	4.7	1
112	Multidisciplinary Approach to Treatment: An Australian Perspective **2017**, 461-476		1
111	Bone Sarcomas in the Adolescent and Young Adult Population. *Pediatric Oncology*, **2017**, 417-427	0.5	
110	Timing and context: important considerations in the return of genetic results to research participants. *Journal of Community Genetics*, **2016**, 7, 11-20	2.5	7
109	Atypical Ewing sarcoma breakpoint region 1 fluorescence in-situ hybridization signal patterns in bone and soft tissue tumours: diagnostic experience with 135 cases. *Histopathology*, **2016**, 69, 1000-1011	7.3	11
108	Sarcoma and germ-line DICER1 mutations - AuthorsRreply. *Lancet Oncology, The*, **2016**, 17, e471	21.7	0

107	Mouse Models of Tumor Immunotherapy. *Advances in Immunology*, **2016**, 130, 1-24	5.6	25
106	The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report. *Clinical Sarcoma Research*, **2016**, 6, 3	2.5	14
105	International survey of awareness of genetic risk in the clinical sarcoma community. *Asia-Pacific Journal of Clinical Oncology*, **2016**, 12, 133-42	1.9	2
104	Clinical Overview of MDM2/X-Targeted Therapies. *Frontiers in Oncology*, **2016**, 6, 7	5.3	215
103	Diagnosis and Management of Hereditary Sarcoma. *Recent Results in Cancer Research*, **2016**, 205, 169-89	1.5	4
102	Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. *Clinical Sarcoma Research*, **2016**, 6, 15	2.5	64
101	Monogenic and polygenic determinants of sarcoma risk: an international genetic study. *Lancet Oncology, The*, **2016**, 17, 1261-71	21.7	121
100	The growing problem of benign connective tissue tumours. *Lancet Oncology, The*, **2015**, 16, 879-80	21.7	5
99	A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma. *Cancer Discovery*, **2015**, 5, 920-31	24.4	71
98	Accepting risk in the acceleration of drug development for rare cancers. *Lancet Oncology, The*, **2015**, 16, e190-4	21.7	8
97	Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. *Clinical Cancer Research*, **2015**, 21, 2029-37	12.9	171
96	Cancer 2015: a longitudinal whole-of-system study of genomic cancer medicine. *Drug Discovery Today*, **2015**, 20, 1429-32	8.8	1
95	Distinguishing activity from progress. *Lancet Oncology, The*, **2015**, 16, 1586-8	21.7	
94	Etiologic, environmental and inherited risk factors in sarcomas. *Journal of Surgical Oncology*, **2015**, 111, 490-5	2.8	18
93	Surveillance recommendations for patients with germline TP53 mutations. *Current Opinion in Oncology*, **2015**, 27, 332-7	4.2	26
92	"Cancer 2015": A Prospective, Population-Based Cancer Cohort-Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic. *Journal of Personalized Medicine*, **2015**, 5, 354-69	3.6	8
91	Clinical implications of genomics for cancer risk genetics. *Lancet Oncology, The*, **2015**, 16, e303-8	21.7	14
90	The life history of neochromosomes revealed. *Molecular and Cellular Oncology*, **2015**, 2, e1000698	1.2	8

89	Stress-induced cellular adaptive strategies: ancient evolutionarily conserved programs as new anticancer therapeutic targets. *BioEssays*, **2014**, 36, 552-60	4.1	8
88	Li-Fraumeni syndrome: cancer risk assessment and clinical management. *Nature Reviews Clinical Oncology*, **2014**, 11, 260-71	19.4	162
87	The architecture and evolution of cancer neochromosomes. *Cancer Cell*, **2014**, 26, 653-67	24.3	122
86	Translational biology of osteosarcoma. *Nature Reviews Cancer*, **2014**, 14, 722-35	31.3	644
85	Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. *BMC Medical Genomics*, **2014**, 7, 23	3.7	170
84	RB1-mediated cell-autonomous and host-dependent oncosuppressor mechanisms in radiation-induced osteosarcoma. *OncoImmunology*, **2014**, 3, e27569	7.2	5
83	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. *Human Molecular Genetics*, **2014**, 23, 6616-33	5.6	77
82	Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling. *Cancer Research*, **2014**, 74, 921-31	10.1	18
81	Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. *Lancet Oncology, The*, **2013**, 14, 901-8	21.7	389
80	Chemical genetics of rapamycin-insensitive TORC2 in S. cerevisiae. *Cell Reports*, **2013**, 5, 1725-36	10.6	27
79	The oncogenic properties of EWS/WT1 of desmoplastic small round cell tumors are unmasked by loss of p53 in murine embryonic fibroblasts. *BMC Cancer*, **2013**, 13, 585	4.8	10
78	Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. *Journal of Pathology*, **2013**, 231, 413-23	9.4	73
77	Genome-wide association study identifies two susceptibility loci for osteosarcoma. *Nature Genetics*, **2013**, 45, 799-803	36.3	156
76	Management of sarcoma in the Asia-Pacific region: resource-stratified guidelines. *Lancet Oncology, The*, **2013**, 14, e562-70	21.7	24
75	The Hippo pathway and human cancer. *Nature Reviews Cancer*, **2013**, 13, 246-57	31.3	1174
74	Multiomics medicine in oncology: assessing effectiveness, cost-effectiveness and future research priorities for the molecularly unique individual. *Pharmacogenomics*, **2013**, 14, 1405-17	2.6	12
73	Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells. *Sarcoma*, **2013**, 2013, 608964	3.1	27
72	Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. *Journal of Clinical Oncology*, **2013**, 31, 2303-12	2.2	119

71	Next-generation sequence analysis of cancer xenograft models. *PLoS ONE*, **2013**, 8, e74432	3.7	23
70	Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation. *Journal of Clinical Investigation*, **2013**, 123, 5351-60	15.9	35
69	High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohort. *PLoS ONE* , **2013**, 8, e69026	3.7	44
68	Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. *Cancer*, **2012**, 118, 1649-55	6.4	171
67	The relationship between unmet needs and distress amongst young people with cancer. *Supportive Care in Cancer*, **2012**, 20, 75-85	3.9	99
66	Hereditary and environmental epidemiology of sarcomas. *Clinical Sarcoma Research*, **2012**, 2, 13	2.5	2
65	Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma. *Pharmacology & Therapeutics*, **2012**, 136, 153-68	13.9	30
64	A newly characterized human well-differentiated liposarcoma cell line contains amplifications of the 12q12-21 and 10p11-14 regions. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2012**, 461, 67-78	5.1	9
63	RANKL, denosumab, and giant cell tumor of bone. *Current Opinion in Oncology*, **2012**, 24, 397-403	4.2	60
62	Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set. *Journal of Clinical Oncology*, **2012**, 30, 2334-9	2.2	24
61	Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma. *OncoImmunology*, **2012**, 1, 1313-1322	7.2	10
60	FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. *Cancer Discovery*, **2012**, 2, 1118-33	24.4	252
59	Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. *Clinical Cancer Research*, **2012**, 18, 4415-24	12.9	300
58	Liposarcoma: molecular genetics and therapeutics. *Sarcoma*, **2011**, 2011, 483154	3.1	110
57	Targeting the p53 Pathway in Ewing Sarcoma. *Sarcoma*, **2011**, 2011, 746939	3.1	27
56	Optimising the management of soft tissue tumours. *Pathology*, **2011**, 43, 295-301	1.6	0
55	Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer. *BMC Cancer*, **2011**, 11, 93	4.8	15
54	Novel approaches to treatment of leiomyosarcomas. *Current Oncology Reports*, **2011**, 13, 316-22	6.3	9

53	Lessons from the deep study of rare tumours. *Journal of Pathology*, **2011**, 224, 306-8	9.4	5
52	RECK in osteosarcoma: a novel role in tumour vasculature and inhibition of tumorigenesis in an orthotopic model. *Cancer*, **2011**, 117, 3517-28	6.4	20
51	Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. *Journal of Clinical Oncology*, **2011**, 29, 2781-6	2.2	38
50	Cyclin E1 is amplified and overexpressed in osteosarcoma. *Journal of Molecular Diagnostics*, **2011**, 13, 289-96	5.1	41
49	Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis. *Clinical Cancer Research*, **2011**, 17, 416-26	12.9	93
48	Starting an adolescent and young adult program: some success stories and some obstacles to overcome. *Journal of Clinical Oncology*, **2010**, 28, 4850-7	2.2	163
47	Adolescent and young adult oncology: an emerging field. *Journal of Clinical Oncology*, **2010**, 28, 4781-2	2.2	94
46	Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. *Lancet Oncology, The*, **2010**, 11, 275-80	21.7	494
45	Safety of denosumab in giant-cell tumour of bone. *Lancet Oncology, The*, **2010**, 11, 815	21.7	25
44	Wnts, bone and cancer. *Journal of Pathology*, **2010**, 220, 1-4	9.4	16
43	Parathyroid hormone-related protein protects against mammary tumor emergence and is associated with monocyte infiltration in ductal carcinoma in situ. *Cancer Research*, **2009**, 69, 7473-9	10.1	34
42	Sarcoma in the young adult population: an international view. *Seminars in Oncology*, **2009**, 36, 227-36	5.5	14
41	Other targetable sarcomas. *Seminars in Oncology*, **2009**, 36, 358-71	5.5	12
40	Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood. *International Journal of Cancer*, **2009**, 125, 426-31	7.5	29
39	Cancer-associated neochromosomes: a novel mechanism of oncogenesis. *BioEssays*, **2009**, 31, 1191-200	4.1	9
38	Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management. *Expert Review of Anticancer Therapy*, **2009**, 9, 1145-57	3.5	33
37	Giant cell tumour of bone. *Current Opinion in Oncology*, **2009**, 21, 338-44	4.2	121
36	Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. *Journal of Clinical Investigation*, **2009**, 119, 837-51	15.9	214

35	No-Man's Land: Between Paediatric and Adult Medical Oncology **2009**, 885-906		
34	The distinctive biology of cancer in adolescents and young adults. *Nature Reviews Cancer*, **2008**, 8, 288-98	31.3	443
33	Molecular profiling of non-small cell lung cancer: of what value in clinical practice?. *Heart Lung and Circulation*, **2008**, 17, 451-62	1.8	1
32	Impaired bone development and increased mesenchymal progenitor cells in calvaria of RB1-/- mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 18402-7	11.5	56
31	Towards social connection for young people with cancer **2008**,		6
30	The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomas. *Expert Review of Molecular Diagnostics*, **2008**, 8, 105-19	3.8	6
29	RECK--a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. *Cancer and Metastasis Reviews*, **2007**, 26, 675-83	9.6	130
28	Dendritic cell immunotherapy for stage IV melanoma. *Melanoma Research*, **2007**, 17, 316-22	3.3	46
27	Adolescents and young adults with cancer: the challenge. *Palliative and Supportive Care*, **2007**, 5, 173-4	2.5	6
26	Molecular pathogenesis of osteosarcoma. *DNA and Cell Biology*, **2007**, 26, 1-18	3.6	238
25	Femoral mesenchymal chondrosarcoma with secondary aneurysmal bone cysts mimicking a small-cell osteosarcoma. *Skeletal Radiology*, **2006**, 35, 311-8	2.7	5
24	High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. *BMC Cancer*, **2006**, 6, 295	4.8	223
23	PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. *BMC Cancer*, **2006**, 6, 53	4.8	71
22	Epigenetic modifications in osteogenic differentiation and transformation. *Journal of Cellular Biochemistry*, **2006**, 98, 757-69	4.7	50
21	Multidisciplinary approach to diagnosis and management of osteosarcoma - a review of the St Vincent's Hospital experience. *International Seminars in Surgical Oncology*, **2006**, 3, 38		13
20	Gene expression profiling of sarcomas. *Pathology*, **2006**, 38, 101-2	1.6	
19	HES1 cooperates with pRb to activate RUNX2-dependent transcription. *Journal of Bone and Mineral Research*, **2006**, 21, 921-33	6.3	46
18	Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. *American Journal of Pathology*, **2005**, 167, 117-28	5.8	111

17	A VEGF/JAK2/STAT5 axis may partially mediate endothelial cell tolerance to hypoxia. *Biochemical Journal*, **2005**, 390, 427-36	3.8	48
16	An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. *Cancer Research*, **2005**, 65, 9633-6	10.1	72
15	Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. *Journal of Cell Biology*, **2004**, 167, 925-34	7.3	180
14	The STATs in cell stress-type responses. *Cell Communication and Signaling*, **2004**, 2, 8	7.5	34
13	Role of the Retinoblastoma Protein in Differentiation and Senescence. *Cancer Biology and Therapy*, **2003**, 2, 124-130	4.6	85
12	STI-571 inhibits in vitro angiogenesis. *Biochemical and Biophysical Research Communications*, **2003**, 310, 135-42	3.4	16
11	A role for alphaV integrin subunit in TGF-beta-stimulated osteoclastogenesis. *Biochemical and Biophysical Research Communications*, **2003**, 307, 1051-8	3.4	14
10	Pilot Study of Oral Eniluracil/5-FU in the Palliation of Hormone-Refractory Prostate Cancer. *Prostate Journal*, **2001**, 3, 30-35		1
9	The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. *Molecular Cell*, **2001**, 8, 303-16	17.6	314
8	Medical Research Council adjuvant trial in high-grade gliomas. *Journal of Clinical Oncology*, **2001**, 19, 3997-9	2.2	6
7	Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation. *Journal of Bone and Mineral Research*, **1999**, 14, 342-50	6.3	136
6	Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. *Journal of Clinical Oncology*, **1999**, 17, 3110-6	2.2	344
5	Altered responsiveness of proximal tubule fluid reabsorption of peritubular angiotensin II in spontaneously hypertensive rats. *Journal of Hypertension*, **1990**, 8, 407-10	1.9	19
4	A 3-dimensional digitizer using spherical co-ordinates. *Australian Dental Journal*, **1988**, 33, 138-43	2.3	1
3	Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. *Nature*, **1987**, 326, 697-8	50.4	250
2	The Medical Genome Reference Bank: Whole genomes and phenotype of 2,570 healthy elderly		1
1	mity: A highly sensitive mitochondrial variant analysis pipeline for whole genome sequencing data		8